27.68USD-1.98%Mkt Cap: 797.07M USDP/E: —Last update: 2026-06-01
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small mole…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap797.07M USD
Enterprise Value439.92M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-25.20M USD
Revenue/Share—
Last Price27.68 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees35
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.23
PEG—
EV/EBITDA-9.83
EV/Revenue—
P/S—
P/B2.35
EPS (TTM)-1.36
EPS (Forward)-4.49
52W Range
13.3671% of range33.47
52W High33.47 USD
52W Low13.36 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-8.37%
ROA-8.05%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-35.21M USD
CapEx (TTM)52.00K USD
FCF Margin—
FCF Yield—
Net Debt-362.17M USD
Net Debt/EBITDA8.09
Balance Sheet
Debt/Equity0.01
Current Ratio35.67
Quick Ratio33.53
Book Value/Sh11.91 USD
Cash/Share12.75 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)45.00 USD
Target Range34.00 USD – 78.00 USD
# Analysts6
Ownership
Shares Out.28.68M
Float18.10M
Insiders0.27%
Institutions106.76%
Short Interest
Short Ratio18.3d
Short % Float16.86%
Short % Out.14.01%
Shares Short4.02M
Short (prev mo.)3.11M
Technical
SMA 5028.25 (-2.0%)
SMA 20021.90 (+26.4%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)151.92K
Avg Vol (10d)165.03K
Technical Indicators
RSI (14)45.1
MACD-0.4101
MACD Signal0.0046
MACD Hist.-0.4147
BB Upper34.15 USD
BB Middle30.04 USD
BB Lower25.93 USD
BB Width27.36%
ATR (14)1.679 USD
Vol Ratio (20d)0.57x